This review highlights phytochemicals' role in overcoming multidrug resistance and improving survival rates in metastatic melanoma, suggesting new avenues for clinical application.
Metastatic melanoma is the most lethal form of skin cancer, accounting for most skin cancer‐related deaths. Immunotherapies and targeted therapies have improved overall and progression‐free survival rates in metastatic melanoma patients. The effectiveness of these therapies decreases due to multidrug resistance (MDR). In contrast to previous reviews, this review extensively highlights the hallmarks of MDR and strategies for reversal of MDR. The review also critically evaluates the challenges in clinical translation of phytochemicals for metastatic melanoma and strategies to overcome these challenges. This review also highlights the various gaps that exist in metastatic melanoma (e.g., vascularized organ‐on‐a‐chip model has not been developed for melanoma which is largely influenced by angiogenesis). These gaps offer novel avenues that could be explored for clinical translation of phytochemicals.
No takes yet. Share an insight, caveat, or question.
Maphutha et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: